{"id":484010,"date":"2021-04-29T07:04:31","date_gmt":"2021-04-29T11:04:31","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/can-fites-phase-iii-psoriasis-study-achieves-75-enrollment-top-line-results-expected-q4-2021\/"},"modified":"2021-04-29T07:04:31","modified_gmt":"2021-04-29T11:04:31","slug":"can-fites-phase-iii-psoriasis-study-achieves-75-enrollment-top-line-results-expected-q4-2021","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/can-fites-phase-iii-psoriasis-study-achieves-75-enrollment-top-line-results-expected-q4-2021\/","title":{"rendered":"Can-Fite\u2019s Phase III Psoriasis Study Achieves 75% Enrollment; Top Line Results Expected Q4 2021"},"content":{"rendered":"

<\/p>\n

Can-Fite\u2019s Phase III Psoriasis Study Achieves 75% Enrollment; Top Line Results Expected Q4 2021<\/b><\/p>\n

Prompted by positive interim analysis data Can-Fite accelerates patient enrollment<\/i><\/b><\/p>\n

PETACH TIKVA, Israel–(BUSINESS WIRE<\/a>)–Can-Fite BioPharma Ltd<\/a>. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced that 75% of patients have been enrolled in its Phase III Comfort\u2122 study designed to establish Piclidenoson\u2019s superiority compared to placebo and non-inferiority compared to Apremilast (Otezla\u00ae) in patients with moderate to severe plaque psoriasis. The Company expects to complete enrollment in Q3 2021 and report topline results in Q4 2021.\n<\/p>\n

\nRecently, the Company conducted an interim analysis with an Independent Data Monitoring Committee (IDMC) which recommended based on the positive data and favorable safety profile to continue patient enrollment. The randomized, double blind study is being conducted in Europe, Israel, and Canada. The study\u2019s primary endpoint is the proportion of patients who achieve a PASI score response of \u226575% (PASI 75) vs. placebo at week 16. Secondary endpoints include non-inferiority to Otezla\u00ae in weeks 16 and 32.\n<\/p>\n

\n\u201cCan-Fite\u2019s lead drug candidate offers several potential key benefits over psoriasis treatments currently on the market. It provides easy administration for patients who tend to prefer oral medications over injectables and has demonstrated a favorable safety profile and positive clinical effect in trials,\u201d stated Can-Fite CEO Dr. Pnina Fishman.\n<\/p>\n

\nPiclidenoson has been out-licensed for the indication of psoriasis in Canada, South Korea, Spain, Austria, Switzerland, Central Eastern European (CEE) countries, Hong Kong, Macau, Taiwan, and China. Can-Fite has received over $20 million in up-front and milestone payments from its distribution agreements to date. According to iHealthcareAnalyst, the psoriasis therapeutic market is estimated to reach $11.3 billion by 2025.\n<\/p>\n

About Piclidenoson<\/b><\/p>\n

\nPiclidenoson is a novel, first-in-class, A3 adenosine receptor agonist (A3AR) small molecule, orally bioavailable drug with a favorable therapeutic index demonstrated in Phase II clinical studies. It is currently being evaluated in a multinational Phase III study as a treatment for moderate to severe psoriasis and a Phase II U.S. study for the treatment of moderate to severe COVID-19.\n<\/p>\n

About Can-Fite BioPharma Ltd.<\/b><\/p>\n

\nCan-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, inflammatory disease and COVID-19. The Company’s lead drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis and a Phase II study in the treatment of moderate COVID-19. Can-Fite’s liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, and successfully achieved its primary endpoint in a Phase II trial for the treatment of non-alcoholic steatohepatitis (NASH). Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company’s third drug candidate, has shown efficacy in the treatment of erectile dysfunction. These drugs have an excellent safety profile with experience in over 1,500 patients in clinical studies to date. For more information please visit: www.can-fite.com<\/a>.\n<\/p>\n

Forward-Looking Statements<\/b><\/p>\n

\nThis press release may contain forward-looking statements, about Can-Fite\u2019s expectations, beliefs or intentions regarding, among other things, market risks and uncertainties, its product development efforts, business, financial condition, results of operations, strategies or prospects. In addition, from time to time, Can-Fite or its representatives have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking words such as \u201cbelieve,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201cmay,\u201d \u201cshould\u201d or \u201canticipate\u201d or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may be included in, but are not limited to, various filings made by Can-Fite with the U.S. Securities and Exchange Commission, press releases or oral statements made by or with the approval of one of Can-Fite\u2019s authorized executive officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause Can-Fite\u2019s actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause Can-Fite\u2019s actual activities or results to differ materially from the activities and results anticipated in such forward-looking statements. Factors that could cause our actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to: our history of losses and needs for additional capital to fund our operations and our inability to obtain additional capital on acceptable terms, or at all; uncertainties of cash flows and inability to meet working capital needs; the impact of the COVID-19 pandemic; the initiation, timing, progress and results of our preclinical studies, clinical trials and other product candidate development efforts; our ability to advance our product candidates into clinical trials or to successfully complete our preclinical studies or clinical trials; our receipt of regulatory approvals for our product candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of our product candidates; our ability to establish and maintain strategic partnerships and other corporate collaborations; the implementation of our business model and strategic plans for our business and product candidates; the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and our ability to operate our business without infringing the intellectual property rights of others; competitive companies, technologies and our industry; statements as to the impact of the political and security situation in Israel on our business; and risks and other risk factors detailed in Can-Fite\u2019s filings with the SEC and in its periodic filings with the TASE. In addition, Can-Fite operates in an industry sector where securities values are highly volatile and may be influenced by economic and other factors beyond its control. Can-Fite does not undertake any obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise.\n<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20210429005261\/en\/<\/a><\/span><\/p>\n

\nCan-Fite BioPharma
\n
Motti Farbstein
\n
info@canfite.com
\n<\/a>
+972-3-9241114\n<\/p>\n

KEYWORDS:<\/b> United States North America Israel Middle East<\/p>\n

INDUSTRY KEYWORDS:<\/b> Oncology Health Other Health Clinical Trials Pharmaceutical Biotechnology<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Can-Fite\u2019s Phase III Psoriasis Study Achieves 75% Enrollment; Top Line Results Expected Q4 2021 Prompted by positive interim analysis data Can-Fite accelerates patient enrollment PETACH TIKVA, Israel–(BUSINESS WIRE)–Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced that 75% of patients have been enrolled in its Phase III Comfort\u2122 study designed to establish Piclidenoson\u2019s superiority compared to placebo and non-inferiority compared to Apremilast (Otezla\u00ae) in patients with moderate to severe plaque psoriasis. The Company expects to complete enrollment in Q3 2021 and report topline results in Q4 2021. Recently, the Company conducted an interim analysis with an Independent Data Monitoring Committee (IDMC) which … <\/p>\n

Continue reading “Can-Fite\u2019s Phase III Psoriasis Study Achieves 75% Enrollment; Top Line Results Expected Q4 2021”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-484010","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nCan-Fite\u2019s Phase III Psoriasis Study Achieves 75% Enrollment; Top Line Results Expected Q4 2021 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/can-fites-phase-iii-psoriasis-study-achieves-75-enrollment-top-line-results-expected-q4-2021\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Can-Fite\u2019s Phase III Psoriasis Study Achieves 75% Enrollment; Top Line Results Expected Q4 2021 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Can-Fite\u2019s Phase III Psoriasis Study Achieves 75% Enrollment; Top Line Results Expected Q4 2021 Prompted by positive interim analysis data Can-Fite accelerates patient enrollment PETACH TIKVA, Israel–(BUSINESS WIRE)–Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced that 75% of patients have been enrolled in its Phase III Comfort\u2122 study designed to establish Piclidenoson\u2019s superiority compared to placebo and non-inferiority compared to Apremilast (Otezla\u00ae) in patients with moderate to severe plaque psoriasis. The Company expects to complete enrollment in Q3 2021 and report topline results in Q4 2021. Recently, the Company conducted an interim analysis with an Independent Data Monitoring Committee (IDMC) which … Continue reading "Can-Fite\u2019s Phase III Psoriasis Study Achieves 75% Enrollment; Top Line Results Expected Q4 2021"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/can-fites-phase-iii-psoriasis-study-achieves-75-enrollment-top-line-results-expected-q4-2021\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-29T11:04:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210429005261r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/can-fites-phase-iii-psoriasis-study-achieves-75-enrollment-top-line-results-expected-q4-2021\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/can-fites-phase-iii-psoriasis-study-achieves-75-enrollment-top-line-results-expected-q4-2021\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Can-Fite\u2019s Phase III Psoriasis Study Achieves 75% Enrollment; Top Line Results Expected Q4 2021\",\"datePublished\":\"2021-04-29T11:04:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/can-fites-phase-iii-psoriasis-study-achieves-75-enrollment-top-line-results-expected-q4-2021\\\/\"},\"wordCount\":1123,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/can-fites-phase-iii-psoriasis-study-achieves-75-enrollment-top-line-results-expected-q4-2021\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210429005261r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/can-fites-phase-iii-psoriasis-study-achieves-75-enrollment-top-line-results-expected-q4-2021\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/can-fites-phase-iii-psoriasis-study-achieves-75-enrollment-top-line-results-expected-q4-2021\\\/\",\"name\":\"Can-Fite\u2019s Phase III Psoriasis Study Achieves 75% Enrollment; Top Line Results Expected Q4 2021 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/can-fites-phase-iii-psoriasis-study-achieves-75-enrollment-top-line-results-expected-q4-2021\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/can-fites-phase-iii-psoriasis-study-achieves-75-enrollment-top-line-results-expected-q4-2021\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210429005261r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2021-04-29T11:04:31+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/can-fites-phase-iii-psoriasis-study-achieves-75-enrollment-top-line-results-expected-q4-2021\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/can-fites-phase-iii-psoriasis-study-achieves-75-enrollment-top-line-results-expected-q4-2021\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/can-fites-phase-iii-psoriasis-study-achieves-75-enrollment-top-line-results-expected-q4-2021\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210429005261r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210429005261r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/can-fites-phase-iii-psoriasis-study-achieves-75-enrollment-top-line-results-expected-q4-2021\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Can-Fite\u2019s Phase III Psoriasis Study Achieves 75% Enrollment; Top Line Results Expected Q4 2021\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Can-Fite\u2019s Phase III Psoriasis Study Achieves 75% Enrollment; Top Line Results Expected Q4 2021 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/can-fites-phase-iii-psoriasis-study-achieves-75-enrollment-top-line-results-expected-q4-2021\/","og_locale":"en_US","og_type":"article","og_title":"Can-Fite\u2019s Phase III Psoriasis Study Achieves 75% Enrollment; Top Line Results Expected Q4 2021 - Market Newsdesk","og_description":"Can-Fite\u2019s Phase III Psoriasis Study Achieves 75% Enrollment; Top Line Results Expected Q4 2021 Prompted by positive interim analysis data Can-Fite accelerates patient enrollment PETACH TIKVA, Israel–(BUSINESS WIRE)–Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced that 75% of patients have been enrolled in its Phase III Comfort\u2122 study designed to establish Piclidenoson\u2019s superiority compared to placebo and non-inferiority compared to Apremilast (Otezla\u00ae) in patients with moderate to severe plaque psoriasis. The Company expects to complete enrollment in Q3 2021 and report topline results in Q4 2021. Recently, the Company conducted an interim analysis with an Independent Data Monitoring Committee (IDMC) which … Continue reading \"Can-Fite\u2019s Phase III Psoriasis Study Achieves 75% Enrollment; Top Line Results Expected Q4 2021\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/can-fites-phase-iii-psoriasis-study-achieves-75-enrollment-top-line-results-expected-q4-2021\/","og_site_name":"Market Newsdesk","article_published_time":"2021-04-29T11:04:31+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210429005261r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/can-fites-phase-iii-psoriasis-study-achieves-75-enrollment-top-line-results-expected-q4-2021\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/can-fites-phase-iii-psoriasis-study-achieves-75-enrollment-top-line-results-expected-q4-2021\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Can-Fite\u2019s Phase III Psoriasis Study Achieves 75% Enrollment; Top Line Results Expected Q4 2021","datePublished":"2021-04-29T11:04:31+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/can-fites-phase-iii-psoriasis-study-achieves-75-enrollment-top-line-results-expected-q4-2021\/"},"wordCount":1123,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/can-fites-phase-iii-psoriasis-study-achieves-75-enrollment-top-line-results-expected-q4-2021\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210429005261r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/can-fites-phase-iii-psoriasis-study-achieves-75-enrollment-top-line-results-expected-q4-2021\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/can-fites-phase-iii-psoriasis-study-achieves-75-enrollment-top-line-results-expected-q4-2021\/","name":"Can-Fite\u2019s Phase III Psoriasis Study Achieves 75% Enrollment; Top Line Results Expected Q4 2021 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/can-fites-phase-iii-psoriasis-study-achieves-75-enrollment-top-line-results-expected-q4-2021\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/can-fites-phase-iii-psoriasis-study-achieves-75-enrollment-top-line-results-expected-q4-2021\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210429005261r1&sid=flmnd&distro=nx&lang=en","datePublished":"2021-04-29T11:04:31+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/can-fites-phase-iii-psoriasis-study-achieves-75-enrollment-top-line-results-expected-q4-2021\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/can-fites-phase-iii-psoriasis-study-achieves-75-enrollment-top-line-results-expected-q4-2021\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/can-fites-phase-iii-psoriasis-study-achieves-75-enrollment-top-line-results-expected-q4-2021\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210429005261r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210429005261r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/can-fites-phase-iii-psoriasis-study-achieves-75-enrollment-top-line-results-expected-q4-2021\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Can-Fite\u2019s Phase III Psoriasis Study Achieves 75% Enrollment; Top Line Results Expected Q4 2021"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/484010","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=484010"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/484010\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=484010"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=484010"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=484010"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}